Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Black cohosh alternative

This article was originally published in The Tan Sheet

Executive Summary

Acatris is positioning its flax lignans ingredient, LinumLife EXTRA, as an alternative to black cohosh for women looking to relieve menopausal symptoms, the firm announces Aug. 24. "Lignans have a balancing effect on hormones because they are phytoestrogens, a plant compound similar to estrogen," a release states. LinumLife EXTRA, which launched earlier this year, can be formulated into one-per-day capsules or tablets; a 250 mg dose of the ingredient provides 50 mg of lignans, Acatris states. Black cohosh has come under review recently from Health Canada and the UK's Medicines & Healthcare products Regulatory Agency regarding safety concerns about the herb's potentially damaging effect on liver function (1"The Tan Sheet," Aug. 28, 2006, In Brief and 2"The Tan Sheet," July 24, 2006, p. 14)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel